文献速递生殖医学妇科

首届卢加诺研讨会:子宫腺肌症在辅助生殖技术中的作用

The First Lugano Workshop on the role of adenomyosis in ART.
PubMed 文献 · Reprod Biomed Online · 2024-09-12

子宫腺肌症患病率不确定,对接受辅助生殖技术(ART)患者的影响临床认知有限。首届卢加诺子宫腺肌症研讨会汇集基础研究、影像、手术和不孕领域专家,讨论MUSA标准在不孕人群的应用、GnRH激动剂联合或不联合芳香化酶抑制剂预处理冻胚移植的前景及治疗未解问题,旨在激发讨论和进一步研究兴趣。

要点

  • 子宫腺肌症特征为雌激素和孕激素信号通路改变,患病率不确定。
  • MUSA超声标准适用于不孕患者,但需更关注直接征象及不同肌层定位尤其内肌层。
  • 除MUSA标准外,还应考虑临床症状和子宫增大程度。

核心结论

  • 子宫腺肌症对ART结局影响临床知识有限,研讨会旨在激发讨论和对子宫腺肌症在不孕中作用的进一步兴趣。

研究设计与样本

  • 首届卢加诺子宫腺肌症研讨会为专题讨论会,涉及子宫腺肌症领域专家,覆盖基础研究、影像、手术和不孕。
  • 本文为意见论文,旨在激发讨论和对子宫腺肌症在不孕中作用的进一步兴趣。

主要发现

  • 子宫腺肌症特征为雌激素和孕激素信号通路改变。
  • MUSA标准适用于不孕患者,但直接征象的存在和在不同肌层尤其内肌层的定位需更多关注。
  • 除MUSA标准外,还应考虑临床症状和子宫增大程度。
  • 冻胚移植周期中GnRH激动剂联合或不联合芳香化酶抑制剂预处理似乎有前景,但许多治疗相关问题仍未解答。

关键数值与推荐

  • MUSA标准适用于不孕患者,但需更关注直接征象及不同肌层尤其内肌层的定位。
  • 除MUSA标准外,还应考虑临床症状和子宫增大程度。
  • 冻胚移植周期中GnRH激动剂联合或不联合芳香化酶抑制剂预处理似乎有前景。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 子宫腺肌症患病率不确定。
  • 对子宫腺肌症影响ART结局的临床知识有限。
  • 冻胚移植周期中GnRH激动剂联合或不联合芳香化酶抑制剂预处理虽似乎有前景,但许多治疗相关问题仍未解答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adenomyosis is an important clinical condition with uncertain prevalence, and clinical focus on adenomyosis in patients undergoing assisted reproductive technology (ART) has increased during recent years. Recognizing the limited clinical knowledge on the impact of adenomyosis on ART outcomes, the First Lugano Adenomyosis Workshop was a symposium involving experts in the field of adenomyosis, covering basic research, imaging, surgery and infertility to highlight current advances and future research areas over a wide range of topics related to adenomyosis. Adenomyosis is characterized by altered oestrogen and progesterone signalling pathways. Although the criteria of the Morphological Uterus Sonographic Assessment (MUSA) Consortium apply to patients with infertility, the presence of direct signs and localization in the different myometrial layers, particularly the inner myometrium, need more focus. In addition to the MUSA criteria, clinical symptoms and the magnitude of uterine enlargement should also be considered. Whilst pre-treatment with gonadotrophin-releasing hormone agonist with or without an aromatase inhibitor in frozen embryo transfer cycles seems promising, many issues related to therapy remain unanswered. During the Workshop, therapeutic progress over the past decades as well as novel insights were presented and discussed. The role of this opinion paper is to stimulate discussion and spark further interest in adenomyosis and the role of adenomyosis in infertility.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Cozzolino M, Bulun S, De Ziegler D, et al. The First Lugano Workshop on the role of adenomyosis in ART. Reprod Biomed Online. 2024. PMID: 39672080. doi:10.1016/j.rbmo.2024.104444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。